Kentucky Retirement Systems Insurance Trust Fund Purchases Shares of 4,632 Illumina, Inc. (NASDAQ:ILMN)

Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,632 shares of the life sciences company's stock, valued at approximately $368,000.

Several other institutional investors have also recently made changes to their positions in the company. Fourth Dimension Wealth LLC acquired a new position in Illumina in the 4th quarter worth about $40,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $45,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Illumina during the 4th quarter valued at approximately $48,000. Finally, Rakuten Securities Inc. lifted its position in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 1.9%

Shares of ILMN opened at $93.23 on Thursday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The firm has a market capitalization of $14.76 billion, a P/E ratio of -15.36, a P/E/G ratio of 1.80 and a beta of 1.32. The firm has a 50-day moving average price of $81.76 and a 200 day moving average price of $100.05. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the previous year, the business earned $0.98 earnings per share. The company's revenue for the quarter was down 1.4% on a year-over-year basis. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Activity at Illumina

In other Illumina news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.60% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ILMN shares. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler cut their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. HSBC downgraded shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a research report on Friday, February 28th. Royal Bank Of Canada lowered their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. Finally, JPMorgan Chase & Co. reduced their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.